MedTrace Logo

Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection

NCT00300768 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2022-12-15

No results posted yet for this study

Summary

The primary purpose of this study was to determine the safety and tolerability of moxidectin in subjects infected with Onchocerca volvulus (a parasitic worm).

Conditions

  • Onchocerciasis

Interventions

DRUG

2 mg moxidectin

Single-dose, tablet encapsulated for blinding

DRUG

ivermectin 150 mcg/kg

Single-dose, tablets encapsulated for blinding

DRUG

4 mg moxidectin

Single dose, tablets encapsulated for blinding

DRUG

8 mg moxidectin

single dose, tablets encapsulated for blinding

Sponsors & Collaborators

Principal Investigators

  • Nicholas Opoku, MD · Onchocerciasis Chemotherapy Research Center, Hohoe, Ghana

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-06
Primary Completion
2009-11-30
Completion
2009-11-29

Countries

  • Ghana

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300768 on ClinicalTrials.gov